Viral Vector Production
Viral Vector Production - Related Videos
08:35
Production and Titering of Recombinant Adeno-associated Viral Vectors
0 Views •
Cited by 149 •
2011
Recombinant adeno-associated virus (rAAVs) vectors are becoming increasingly valuable for in vivo studies in animals. We describe how rAAVs can be produced in the laboratory and how these vectors can be titered to give an accurate reading of the number of infectious particles produced.
10:42
A Protocol for the Production of Integrase-deficient Lentiviral Vectors for CRISPR/Cas9-mediated Gene Knockout in Dividing Cells
0 Views •
Cited by 21 •
2017
We describe the production strategy of integrase-deficient lentiviral vectors (IDLVs) as vehicles for delivering CRISPR/Cas9 to cells. With an ability to mediate quick and robust gene editing in cells, IDLVs present a safer and equally effective vector platform for gene delivery compared to integrase-competent vectors.
03:20
Large-Scale Production of High-Capacity Adenoviral Vectors
0 Views •
2026
Source: Ehrke-Schulz, E., et al. Cloning and Large-Scale Production of High-Capacity Adenoviral Vectors Based on the Human Adenovirus Type 5. J. Vis. Exp. (2016)This video demonstrates the large-scale amplification of high-capacity adenoviral vectors in suspension-adapted human embryonic kidney cells expressing Cre recombinase for use in gene delivery applications requiring high-titer, helper-free vector preparations.
08:47
Intracranial Injection of Adeno-associated Viral Vectors
0 Views •
Cited by 56 •
2010
Here we present the intracranial injection of AAV vectors for fluorescent labeling of neurons and glia in the visual cortex.
08:33
Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector
0 Views •
Cited by 12 •
2016
This manuscript describes how viral vector-mediated local gene delivery provides an attractive way to express transgenes in the central nervous system. The protocol outlines all crucial steps to perform a viral vector injection in the substantia nigra of the rat to develop a viral vector-based animal model for Parkinson's disease.
FAQs
The vector genome supplies the genetic payload, while essential viral proteins provide the components needed for particle formation. Introducing both into producer cells creates a system in which payload packaging and particle assembly can occur together. This division of roles allows researchers to engineer what is delivered while retaining the machinery required to generate particles.
Consistency matters because variation in generation can affect whether separate preparations support comparable experiments or applications. Standardized handling of genome introduction, protein availability, particle assembly, harvesting, and purification helps produce material with more predictable characteristics. This is especially important when viral vectors are used to compare immune responses or evaluate therapeutic approaches.
Replication-competent virus is a critical safety concern because it would indicate that a preparation contains virus capable of replicating rather than only the intended vector particles. Quality control therefore includes testing for this contaminant alongside checks of potency, identity, and safety. Detecting it helps determine whether a preparation is suitable for research or clinical use.
A typical workflow moves from introducing the vector genome and essential viral proteins into producer cells to allowing particle assembly, harvesting the resulting material, purifying it, and performing quality tests. Each stage serves a different purpose: generation creates particles, purification prepares the material for use, and testing assesses potency, identity, safety, and contamination.
In vaccine development, viral vectors can present pathogen-derived antigens to the immune system, making them useful tools for examining vaccine concepts and host responses. Production quality directly affects how confidently investigators interpret those studies: potency and identity testing help establish that the material has the intended characteristics before immune effects are evaluated.
Beyond vaccines, viral vector production supports studies of host responses, gene function, and immune therapies. In immunology and infection research, these applications let investigators connect delivered genetic material with questions about pathogen-related immunity or therapeutic activity. The same platform therefore serves both mechanistic research and development-oriented work, provided preparations meet relevant quality and safety expectations.